Image Description (Celltrion Logo)
Memantine Hydrochloride
Product Images NDC 71335-1863
11 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1863). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label (Lbl713351863)
Memantine Hcl 10mg Tablet label from Bryant Ranch Prepack. The label compares this product to Namenda 10mg Tablet by Vivimed Life Sciences. It indicates a package size of 30 tablets with storage instructions to keep at 20°-25°C (68°-77°F) and a warning to keep drugs out of reach of children. The label shows the NDC 71335-1863-1 and includes a barcode and lot number 1523487.*
Structure (Memantinehcltab Figure 01)
Chemical structure of Memantine Hydrochloride, showing its molecular framework with annotated functional groups NH2 and HCl, and methyl substituents.*
Figure1 (Memantinehcltab Figure 02)
A line graph showing the mean change from baseline in ADCS-ADL Score over 28 weeks of treatment comparing Memantine Hydrochloride and placebo groups. The graph includes error bars and indicates both clinical improvement and decline, with Memantine HCl data represented by circles and placebo data by squares.*
Figure2 (Memantinehcltab Figure 03)
A cumulative percentage of patients chart comparing Memantine Hydrochloride (MEMANTINE HCl) and placebo groups. The x-axis measures ADCS-ADL change from baseline, ranging from 10 to -25, and the y-axis shows cumulative percentage of patients from 0 to 100%. Memantine HCl group is marked with open circles and placebo with solid squares, showing a higher cumulative percentage of patients at each level of ADCS-ADL change for Memantine HCl.*
Figure3 (Memantinehcltab Figure 04)
Line graph depicting mean change from baseline in SIB scores over 28 weeks of treatment, comparing Memantine Hydrochloride and placebo groups. The graph shows clinical improvement and decline thresholds, with error bars representing SEM. Memantine HCl group maintains near baseline scores, while placebo group shows decline over time.*
Figure4 (Memantinehcltab Figure 05)
A cumulative percentage graph comparing the effects of Memantine Hydrochloride versus placebo on SIB change from baseline in patients. The x-axis shows SIB change from baseline, ranging from about 15 to -30, and the y-axis shows the cumulative percentage of patients from 0% to 100%. Memantine HCl is represented with circles, and placebo with squares, illustrating a higher cumulative percentage of patients experiencing greater SIB changes with Memantine HCl.*
Figure5 (Memantinehcltab Figure 06)
A line graph showing the mean change from baseline in ADCS-ADL score over a 24-week treatment period. It compares two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis measures mean change ± SEM, indicating clinical improvement or decline, while the x-axis represents weeks of treatment. Memantine HCl/Donepezil shows less decline over time compared to Placebo/Donepezil.*
Figure6 (Memantinehcltab Figure 07)
A cumulative percentage of patients chart displaying ADCS-ADL change from baseline. The graph compares two groups: Placebo/Donepezil and Memantine HCl/Donepezil, indicated by square and circle markers respectively, showing the distribution of patient changes across a range of values.*
Figure7 (Memantinehcltab Figure 08)
A line graph comparing mean change from baseline in SIB score over 24 weeks of treatment between two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis measures mean change (± SEM) from baseline with positive values indicating clinical improvement and negative values clinical decline. The x-axis shows weeks of treatment from 0 to 24. Memantine HCl/Donepezil exhibits initial increase and higher improvement scores, while Placebo/Donepezil shows minimal change followed by decline.*
Figure8 (Memantinehcltab Figure 09)
A cumulative percentage graph comparing patients on Placebo/Donepezil to those on Memantine Hydrochloride/Donepezil. The x-axis represents the SIB change from baseline, ranging from 20 to -30, and the y-axis shows the cumulative percentage of patients from 0 to 100%. Two curves are depicted: one with squares for Placebo/Donepezil and one with circles for Memantine HCl/Donepezil.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
